SOPH logo

SOPHiA GENETICS SA (SOPH) Company Overview

Profile

Full Name:

SOPHiA GENETICS SA

Sector:

Healthcare

Country:

Switzerland

IPO:

July 23, 2021

Indexes:

Not included

Description:

SOPH (SOPHiA GENETICS SA) is a biotechnology company that uses data-driven medicine to improve patient care. They provide advanced genomic analysis tools to help doctors diagnose diseases and personalize treatments, making healthcare more effective and accessible for patients worldwide.

Key Details

Price

$3.57

Annual Revenue

$62.37 M(+31.14% YoY)

Annual EPS

-$1.22(+10.29% YoY)

Annual ROE

-44.93%

Beta

0.11

Events Calendar

Earnings

Next earnings date:

Mar 5, 2025

Recent quarterly earnings:

Nov 5, 2024

Recent annual earnings:

Mar 5, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 18, 24 Craig-Hallum
Buy
Aug 7, 24 RBC Capital
Outperform
Jun 27, 24 Guggenheim
Buy
Mar 6, 24 RBC Capital
Outperform
Mar 6, 24 BTIG
Buy
Jan 12, 24 RBC Capital
Outperform
Nov 29, 23 RBC Capital
Outperform
May 10, 23 Morgan Stanley
Overweight
May 10, 23 Credit Suisse
Neutral
Mar 8, 23 Morgan Stanley
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
SOPH
prnewswire.comJanuary 28, 2025

The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland , Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights.

SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPH
seekingalpha.comNovember 5, 2024

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today.

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
SOPH
prnewswire.comNovember 5, 2024

BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO.

SOPHiA GENETICS Reports Third Quarter 2024 Results
SOPHiA GENETICS Reports Third Quarter 2024 Results
SOPHiA GENETICS Reports Third Quarter 2024 Results
SOPH
prnewswire.comNovember 5, 2024

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter  2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectively Operating loss was $15.4 million on a reported basis and $10.6 million on an adjusted basis, representing year-over-year improvements of 7.1% and 10.4%, respectively Cash burn was $9.6 million, representing a year-over-year improvement of 39.1% The company reiterates full-year guidance, including revenue between $65 million and $67 million, adjusted gross margin of 72.0% to 72.5%, and adjusted operating loss between $45 million and $50 million "Record analysis volume drove a reacceleration of Clinical growth across most key geographies in Q3, with volume increasing 16% year-over-year, offset by expected softness in BioPharma," said Jurgi Camblong, PhD.

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
SOPH
prnewswire.comOctober 22, 2024

BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
SOPH
prnewswire.comSeptember 14, 2024

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024.

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
SOPH
prnewswire.comSeptember 12, 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
SOPH
prnewswire.comSeptember 12, 2024

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY.

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
SOPH
prnewswire.comSeptember 5, 2024

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio.

What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
SOPH
zacks.comAugust 9, 2024

SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for SOPHiA GENETICS SA?
  • Does SOPHiA GENETICS SA pay dividends?
  • What sector is SOPHiA GENETICS SA in?
  • What industry is SOPHiA GENETICS SA in?
  • What country is SOPHiA GENETICS SA based in?
  • When did SOPHiA GENETICS SA go public?
  • Is SOPHiA GENETICS SA in the S&P 500?
  • Is SOPHiA GENETICS SA in the NASDAQ 100?
  • Is SOPHiA GENETICS SA in the Dow Jones?
  • When was SOPHiA GENETICS SA's last earnings report?
  • When does SOPHiA GENETICS SA report earnings?
  • Should I buy SOPHiA GENETICS SA stock now?

What is the ticker symbol for SOPHiA GENETICS SA?

The ticker symbol for SOPHiA GENETICS SA is NASDAQ:SOPH

Does SOPHiA GENETICS SA pay dividends?

No, SOPHiA GENETICS SA does not pay dividends

What sector is SOPHiA GENETICS SA in?

SOPHiA GENETICS SA is in the Healthcare sector

What industry is SOPHiA GENETICS SA in?

SOPHiA GENETICS SA is in the Health Information Services industry

What country is SOPHiA GENETICS SA based in?

SOPHiA GENETICS SA is headquartered in Switzerland

When did SOPHiA GENETICS SA go public?

SOPHiA GENETICS SA's initial public offering (IPO) was on July 23, 2021

Is SOPHiA GENETICS SA in the S&P 500?

No, SOPHiA GENETICS SA is not included in the S&P 500 index

Is SOPHiA GENETICS SA in the NASDAQ 100?

No, SOPHiA GENETICS SA is not included in the NASDAQ 100 index

Is SOPHiA GENETICS SA in the Dow Jones?

No, SOPHiA GENETICS SA is not included in the Dow Jones index

When was SOPHiA GENETICS SA's last earnings report?

SOPHiA GENETICS SA's most recent earnings report was on Nov 5, 2024

When does SOPHiA GENETICS SA report earnings?

The next expected earnings date for SOPHiA GENETICS SA is Mar 5, 2025

Should I buy SOPHiA GENETICS SA stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions